- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Chiesi signs $1.9bn deal to buy KalVista and its HAE drug | ||
| Mi | AZ will invest £300m in UK, says PM Keir Starmer | ||
| Mi | Amgen, AZ will pilot FDA's real-time clinical trial plan | ||
| Mi | AZ, Amgen will pilot FDA's real-time clinical trial plan | ||
| Mi | First-quarter sales strength buoys new GSK CEO Miels | ||
| Mi | UK study finds clue to rising cancer rates in younger people | ||
| Di | Merck KGaA partners Remepy in PDURS-focused alliance | ||
| Di | AI start-up Profluent nabs Lilly as first big pharma partner | ||
| Di | Can Purdue finally get its bankruptcy plan over the line? | ||
| Di | GSK eyes October FDA verdict on chronic hep B drug | ||
| Di | Novartis shares fall as Entresto sales weaken | ||
| Di | Boehringer/Zealand dual-acting drug causes 16.6% weight loss | ||
| Mo | Intellia files CRISPR drug after historic phase 3 readout | ||
| Mo | Lilly's M&A team strikes again with $2.3bn Ajax takeover | ||
| Mo | GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio | ||
| Mo | Lilly falls on slower start for Foundayo versus Wegovy | ||
| Mo | New NIHR-funded TRC for Parkinson's disease | ||
| Mo | Sun sets out $11.75bn takeover play for Organon | ||
| Fr | FDA grants three priority vouchers to psychedelics | ||
| Fr | FDA declines to approve AbbVie's Botox follow-up | ||
| Fr | FDA clears first genetic hearing loss gene therapy | ||
| 23.04. | Trump's DOJ reschedules medicinal marijuana, increasing access | ||
| 23.04. | Ray's upscaled Series B, and other biofinancings | ||
| 23.04. | UK Biobank patient data placed on sale in China | ||
| 23.04. | Novo says oral semaglutide works in diabetic kids |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.